Relay Therapeutics, Inc. (RLAY) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2025. Relay Therapeutics is a clinical-stage precision medicine company utilizing its Dynamo® platform to discover small molecule therapeutics for targeted oncology and genetic diseases. The company has no products approved for commercial sale and has not generated revenue from product sales. Its lead product candidate, RLY-2608 (a PI3Kα inhibitor), is in Phase 3 development for breast cancer, and the company is advancing other candidates including RLY-8161 (NRAS inhibitor) and a non-inhibitory chaperone for Fabry disease.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $8.4 million | $10.0 million |
| Net Loss | $(74.1) million | $(88.1) million | $(221.6) million | $(261.7) million |
| Net Loss Per Share | $(0.43) | $(0.63) | $(1.30) | $(1.94) |
| R&D Expenses | $68.3 million | $76.6 million | $206.0 million | $251.0 million |
| G&A Expenses | $12.1 million | $19.8 million | $44.5 million | $59.7 million |
| Cash & Investments | $596.4 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $1.96 billion (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue: Q3 2025 revenue was $0, compared to $0 in Q3 2024. YTD 2025 revenue of $8.4 million was recognized from the Elevar Therapeutics agreement, down from $10.0 million in YTD 2024 (derived from the Genentech agreement).
- Expense Reduction: Total operating expenses decreased by $16.0 million in Q3 2025 compared to Q3 2024. This was driven by a $8.4 million decrease in R&D and a $7.6 million decrease in G&A, attributed to strategic streamlining of the research organization and reduced stock compensation expenses.
- Collaboration Changes:
- Genentech: The collaboration agreement for migoprotafib (RLY-1971) was terminated by Genentech without cause effective January 7, 2025. No further milestones are expected.
- Elevar: In December 2024, the company licensed lirafugratinib (RLY-4008) to Elevar Therapeutics, receiving $8.4 million in upfront and material transfer consideration recognized in YTD 2025.
- Asset Impairment: The company wrote off a $2.3 million intangible asset (assembled workforce from the ZebiAI acquisition) in the first half of 2025 following the involuntary termination of over 70 employees.
- Lease Restructuring: The company terminated its lease at 399 Binney Street and entered a new lease at 300 OKS in Cambridge, MA, incurring a $2.5 million termination payment and a $3.5 million relocation payment.
Guidance, Outlook, and Risks
- Liquidity: Management believes cash, cash equivalents, and investments of $596.4 million are sufficient to fund operations into 2029. No debt is outstanding.
- Clinical Progress:
- RLY-2608: Initiated the global Phase 3 ReDiscover-2 Trial in Q2 2025 for HR+/HER2- advanced breast cancer. Updated interim data from the ReDiscover Trial showed a median progression-free survival of 10.3 months overall.
- ReInspire Trial: Initiated in Q1 2025 for PIK3CA-related overgrowth spectrum (PROS).
- Key Risks:
- Capital Needs: The company expects to incur significant losses for the foreseeable future and will require additional financing to complete development and commercialization.
- Regulatory & Clinical: No products are approved; success depends on clinical trial outcomes and regulatory approvals which are uncertain.
- Third-Party Reliance: Reliance on third parties for clinical trials and manufacturing introduces execution risks.
- Legal Proceedings: A derivative lawsuit filed in December 2024 alleges excessive director compensation; the case is currently in discovery.
Investor Verification Checklist
- Cash Runway: Verify the $596.4 million cash position and the assumption that it funds operations into 2029 given the high burn rate (~$220M net loss YTD).
- RLY-2608 Phase 3: Monitor enrollment rates and interim data readouts for the ReDiscover-2 Trial, which is critical for the company's valuation.
- Genentech Termination Impact: Assess the long-term impact of losing the Genentech partnership and the lack of future milestone revenue from that asset.
- Elevar Milestones: Track the development progress of lirafugratinib by Elevar Therapeutics to determine the likelihood of receiving the potential $495 million in milestone payments.
- Legal Exposure: Monitor the status of the derivative lawsuit regarding director compensation for potential financial or reputational impact.